iwNHL 2015 | Selinexor, selective inhibitor of nuclear export, for non-Hodgkin lymphoma

Name: Selinexor, selective inhibitor of nuclear export, for non-Hodgkin lymphoma
Uploaded: 2015-10-03T00:00:00.000Z
Duration: 3 min 36 s
Description: At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, John Kuruvilla, MD, of Princess Margaret Cancer Centre, Toronto, Canada, discusses the early clinical activity of selinexor, an oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist, for the treatment of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and Richter's transformation.

John Kuruvilla • 3 Oct 2015

iwNHL 2015

Diffuse Large B-Cell Lymphoma Non-Hodgkin Lymphoma Selinexor

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, John Kuruvilla, MD, of Princess Margaret Cancer Centre, Toronto, Canada, discusses the early clinical activity of selinexor, an oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist, for the treatment of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and Richter’s transformation.